阿替唑单抗
医学
内科学
养生
肿瘤科
人口
化疗
癌症
免疫疗法
彭布罗利珠单抗
环境卫生
作者
S.M. Lee,Baohui Han,S. Peters,Anh‐Tuan Le,Dingzhi Huang,Gang Wu,Lejie Cao,Cam Phuong Pham,Jun Zhao,K. Wang,Nong Yang,Hua Zhong,Youyou Hu,Stefanie Morris,Vincent Lam,Vilma Graupner,Barbara J. Gitlitz,Elen Höglander,Christian Schulz
标识
DOI:10.1016/j.jtho.2023.09.1168
摘要
IPSOS (NCT03191786) is the first global, multicenter, open-label, randomised Phase III study to show that, in patients with NSCLC ineligible for platinum-doublet chemotherapy (PDC), atezolizumab significantly improved OS vs single-agent chemotherapy in the intention-to-treat (ITT) population (stratified HR, 0.78; 95% CI: 0.63, 0.97; P=0.028; median follow-up, 41.0 months). A consistent benefit was shown across key subgroups, including subgroups according to PD-L1 expression, and no new or unexpected safety concerns were observed.
科研通智能强力驱动
Strongly Powered by AbleSci AI